The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death

Michelle Ferguson, M. Gloria Luciani, Lee Finlan, Elaine M. Rankin, Sally Ibbotson, Alan Fersht, Ted R. Hupp (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    Cyclin-dependent protein kinases play important roles in cell cycle progression and are attractive targets for the design of anti-proliferative drugs. Two distinct synthetic CDK1/2 inhibitors, Roscovitine and NU2058, are pharmacologically distinct in their ability to modify p53-dependent transcription and perturb cell cycle progression. Although such active-site CDK1/2 inhibitors comprise the most standard type of enzyme inhibitor, many protein kinases are proving to harbour high affinity docking sites that may provide a potentially novel interface for the design of kinase-inhibitors. We examined whether CDK2 has a docking site for its oligomeric substrate p53, whether small-peptide leads can be developed that inhibit CDK2 function, and whether such peptide-inhibitors are pharmacologically distinct from Roscovitine or NU2058. A docking site for CDK2 was identified in the tetramerization domain of p53 at a site that is distinct from the phospho-acceptor site. Peptides derived from the tetramerization domain of p53 block CDK2 phosphorylation and identification of critical CDK2 contacts in the tetramerization domain of p53 suggest that kinase docking does not require tetramerization of the substrate. Transient transfection assays were developed to show that the GFP-CDK2 docking site fusion protein (GFP-CIP) attenuates p53 activity in vivo and suppresses p21WAF1 induction which is similar to NU2058 but distinct from Roscovitine. A stable cell line with an inducible GFP-CIP gene attenuates p53 activity and induces significant cell death in a drug-resistant melanoma cell line, sensitizes cells to death induced by Doxorubicin, and suppresses cell growth in a colony formation assay. These data indicate that CDK2, in addition to cyclin A, can have a high affinity docking site for a substrate and highlights the possibility that CDK2 docking sites may represent effective targets for inhibitor design.

    Original languageEnglish
    Pages (from-to)80-89
    Number of pages10
    JournalCell Cycle
    Volume3
    Issue number1
    DOIs
    Publication statusPublished - Jan 2004

    Fingerprint

    Cell Death
    Peptides
    Cell Cycle
    Phosphotransferases
    Cyclin A
    Cell Line
    Cyclin-Dependent Kinases
    p53 Genes
    Enzyme Inhibitors
    Pharmaceutical Preparations
    Doxorubicin
    Protein Kinases
    Transfection
    Melanoma
    Catalytic Domain
    Phosphorylation
    Growth
    NU2058
    roscovitine
    Proteins

    Keywords

    • CDK2
    • GFP
    • p53
    • Peptide
    • Transcription

    Cite this

    Ferguson, M., Luciani, M. G., Finlan, L., Rankin, E. M., Ibbotson, S., Fersht, A., & Hupp, T. R. (2004). The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death. Cell Cycle, 3(1), 80-89. https://doi.org/10.4161/cc.3.1.603
    Ferguson, Michelle ; Luciani, M. Gloria ; Finlan, Lee ; Rankin, Elaine M. ; Ibbotson, Sally ; Fersht, Alan ; Hupp, Ted R. / The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death. In: Cell Cycle. 2004 ; Vol. 3, No. 1. pp. 80-89.
    @article{ff298ea6f401465facf0a80252e1427e,
    title = "The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death",
    abstract = "Cyclin-dependent protein kinases play important roles in cell cycle progression and are attractive targets for the design of anti-proliferative drugs. Two distinct synthetic CDK1/2 inhibitors, Roscovitine and NU2058, are pharmacologically distinct in their ability to modify p53-dependent transcription and perturb cell cycle progression. Although such active-site CDK1/2 inhibitors comprise the most standard type of enzyme inhibitor, many protein kinases are proving to harbour high affinity docking sites that may provide a potentially novel interface for the design of kinase-inhibitors. We examined whether CDK2 has a docking site for its oligomeric substrate p53, whether small-peptide leads can be developed that inhibit CDK2 function, and whether such peptide-inhibitors are pharmacologically distinct from Roscovitine or NU2058. A docking site for CDK2 was identified in the tetramerization domain of p53 at a site that is distinct from the phospho-acceptor site. Peptides derived from the tetramerization domain of p53 block CDK2 phosphorylation and identification of critical CDK2 contacts in the tetramerization domain of p53 suggest that kinase docking does not require tetramerization of the substrate. Transient transfection assays were developed to show that the GFP-CDK2 docking site fusion protein (GFP-CIP) attenuates p53 activity in vivo and suppresses p21WAF1 induction which is similar to NU2058 but distinct from Roscovitine. A stable cell line with an inducible GFP-CIP gene attenuates p53 activity and induces significant cell death in a drug-resistant melanoma cell line, sensitizes cells to death induced by Doxorubicin, and suppresses cell growth in a colony formation assay. These data indicate that CDK2, in addition to cyclin A, can have a high affinity docking site for a substrate and highlights the possibility that CDK2 docking sites may represent effective targets for inhibitor design.",
    keywords = "CDK2, GFP, p53, Peptide, Transcription",
    author = "Michelle Ferguson and Luciani, {M. Gloria} and Lee Finlan and Rankin, {Elaine M.} and Sally Ibbotson and Alan Fersht and Hupp, {Ted R.}",
    year = "2004",
    month = "1",
    doi = "10.4161/cc.3.1.603",
    language = "English",
    volume = "3",
    pages = "80--89",
    journal = "Cell Cycle",
    issn = "1538-4101",
    publisher = "Taylor & Francis",
    number = "1",

    }

    Ferguson, M, Luciani, MG, Finlan, L, Rankin, EM, Ibbotson, S, Fersht, A & Hupp, TR 2004, 'The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death', Cell Cycle, vol. 3, no. 1, pp. 80-89. https://doi.org/10.4161/cc.3.1.603

    The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death. / Ferguson, Michelle; Luciani, M. Gloria; Finlan, Lee; Rankin, Elaine M.; Ibbotson, Sally; Fersht, Alan; Hupp, Ted R. (Lead / Corresponding author).

    In: Cell Cycle, Vol. 3, No. 1, 01.2004, p. 80-89.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death

    AU - Ferguson, Michelle

    AU - Luciani, M. Gloria

    AU - Finlan, Lee

    AU - Rankin, Elaine M.

    AU - Ibbotson, Sally

    AU - Fersht, Alan

    AU - Hupp, Ted R.

    PY - 2004/1

    Y1 - 2004/1

    N2 - Cyclin-dependent protein kinases play important roles in cell cycle progression and are attractive targets for the design of anti-proliferative drugs. Two distinct synthetic CDK1/2 inhibitors, Roscovitine and NU2058, are pharmacologically distinct in their ability to modify p53-dependent transcription and perturb cell cycle progression. Although such active-site CDK1/2 inhibitors comprise the most standard type of enzyme inhibitor, many protein kinases are proving to harbour high affinity docking sites that may provide a potentially novel interface for the design of kinase-inhibitors. We examined whether CDK2 has a docking site for its oligomeric substrate p53, whether small-peptide leads can be developed that inhibit CDK2 function, and whether such peptide-inhibitors are pharmacologically distinct from Roscovitine or NU2058. A docking site for CDK2 was identified in the tetramerization domain of p53 at a site that is distinct from the phospho-acceptor site. Peptides derived from the tetramerization domain of p53 block CDK2 phosphorylation and identification of critical CDK2 contacts in the tetramerization domain of p53 suggest that kinase docking does not require tetramerization of the substrate. Transient transfection assays were developed to show that the GFP-CDK2 docking site fusion protein (GFP-CIP) attenuates p53 activity in vivo and suppresses p21WAF1 induction which is similar to NU2058 but distinct from Roscovitine. A stable cell line with an inducible GFP-CIP gene attenuates p53 activity and induces significant cell death in a drug-resistant melanoma cell line, sensitizes cells to death induced by Doxorubicin, and suppresses cell growth in a colony formation assay. These data indicate that CDK2, in addition to cyclin A, can have a high affinity docking site for a substrate and highlights the possibility that CDK2 docking sites may represent effective targets for inhibitor design.

    AB - Cyclin-dependent protein kinases play important roles in cell cycle progression and are attractive targets for the design of anti-proliferative drugs. Two distinct synthetic CDK1/2 inhibitors, Roscovitine and NU2058, are pharmacologically distinct in their ability to modify p53-dependent transcription and perturb cell cycle progression. Although such active-site CDK1/2 inhibitors comprise the most standard type of enzyme inhibitor, many protein kinases are proving to harbour high affinity docking sites that may provide a potentially novel interface for the design of kinase-inhibitors. We examined whether CDK2 has a docking site for its oligomeric substrate p53, whether small-peptide leads can be developed that inhibit CDK2 function, and whether such peptide-inhibitors are pharmacologically distinct from Roscovitine or NU2058. A docking site for CDK2 was identified in the tetramerization domain of p53 at a site that is distinct from the phospho-acceptor site. Peptides derived from the tetramerization domain of p53 block CDK2 phosphorylation and identification of critical CDK2 contacts in the tetramerization domain of p53 suggest that kinase docking does not require tetramerization of the substrate. Transient transfection assays were developed to show that the GFP-CDK2 docking site fusion protein (GFP-CIP) attenuates p53 activity in vivo and suppresses p21WAF1 induction which is similar to NU2058 but distinct from Roscovitine. A stable cell line with an inducible GFP-CIP gene attenuates p53 activity and induces significant cell death in a drug-resistant melanoma cell line, sensitizes cells to death induced by Doxorubicin, and suppresses cell growth in a colony formation assay. These data indicate that CDK2, in addition to cyclin A, can have a high affinity docking site for a substrate and highlights the possibility that CDK2 docking sites may represent effective targets for inhibitor design.

    KW - CDK2

    KW - GFP

    KW - p53

    KW - Peptide

    KW - Transcription

    UR - http://www.scopus.com/inward/record.url?scp=2942673177&partnerID=8YFLogxK

    U2 - 10.4161/cc.3.1.603

    DO - 10.4161/cc.3.1.603

    M3 - Article

    VL - 3

    SP - 80

    EP - 89

    JO - Cell Cycle

    JF - Cell Cycle

    SN - 1538-4101

    IS - 1

    ER -